Renovo is well funded and its future strategy is aimed at maximising shareholder value. The Company will consider all options available to it which may include acquisitions and mergers of external companies in addition to realising value where possible from its current portfolio of clinical and preclinical candidates and intellectual property. The directors do not intend to place any restrictions on the nature of the business carried out by potential acquisition and merger targets. Renovo’s cost base is being minimised wherever possible in order to maximise the Company’s available cash.
Printer-friendly version